$APVO News

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)".

Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology Programs

Aptevo Therapeutic Announces 87% clinical benefit rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection

Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate

Aptevo Therapeutics shares are trading lower after the company announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are either elderly or unfit for intensive chemotherapy.

Aptevo Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine In Newly Diagnosed AML Patients; Trials Deliver 86% Clinical Benefit Rate With Zero Patients Experiencing Common Symptom Of CRS

12 Health Care Stocks Moving In Tuesday's After-Market Session

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Aptevo Therapeutics President, CEO Marvin White To Retire, Effective April 1, Transitioning To Executive Chair; COO Jeff Lamothe Appointed President, CEO

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

APVO stock has given up its prior gain. Aptevo Therapeutics shares were trading higher after the company entered into a $60 million equity line of credit agreement with Yorkville Advisors Global.

Aptevo Therapeutics shares are trading higher after the company entered into a $60 million equity line of credit agreement with Yorkville Advisors Global.

Aptevo Therapeutics Enters $60M Equity Line Of Credit Agreement With Yorkville Advisors Global, LP

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

What's Going On With Aptevo Therapeutics Stock Today?

Aptevo Therapeutics To Implement 1-For-18 Reverse Stock Split Effective Dec. 29, With Split-Adjusted Trading To Begin Dec. 30, 2025

Aptevo Therapeutics shares are trading lower after the company announced a 1-for-18 reverse stock split.

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025